Skip to Content

Intellia’s Journey

Leading the genome
editing revolution

The discovery of CRISPR by Intellia co-founder Jennifer Doudna and her colleague Emmanuelle Charpentier captured the world’s attention for its potential to revolutionize how we treat disease. That opportunity drives Intellia in its mission to transform the lives of people with severe diseases through curative genome editing treatments.

Learn more about our history and join us in the continuing journey toward a new era of medicine.

November 2014

Intellia Therapeutics Founded

Intellia is founded to transform the lives of people with severe diseases by developing curative genome editing treatments.

January 2015

Novartis Collaboration Established

Intellia initiates its first collaboration with Novartis to develop novel cell therapies using Intellia’s ex vivo CRISPR/Cas9 platform — marking an important validation of Intellia’s team and capabilities.

April 2016

Regeneron Collaboration Began

Intellia begins a collaboration with Regeneron focused on in vivo applications of CRISPR/Cas9. Partnership further expanded in 2020.

August 2016

Lipid Nanoparticle (LNP) Delivery System Established

Intellia demonstrates its foundational proprietary lipid nanoparticle (LNP) delivery system in preclinical studies, paving the way to precisely deliver CRISPR/Cas9 to target cells — the central technical challenge to creating potentially curative in vivo genome editing treatments in humans.

March 2018

First In Vivo Genome Editing in Non-Human Primates

Intellia demonstrates editing of the TTR gene in liver cells of non-human primates with therapeutically relevant reduction of serum TTR protein.

October 2020

Nobel Prize Awarded to Jennifer Doudna and Emmanuelle Charpentier

Intellia co-founder Jennifer Doudna and colleague Emmanuelle Charpentier win the Nobel Prize in Chemistry for the discovery of CRISPR/Cas9.

March 2021

Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow

Intellia demonstrates systemic in vivo genome editing in a tissue outside the liver in preclinical models, supporting the potential for a less invasive treatment of sickle cell disease and other inherited blood disorders and reinforcing the promise of Intellia’s modular platform.

June 2021

First-Ever Clinical Data for In Vivo CRISPR Genome Editing

Intellia and Regeneron make history by announcing interim Phase 1 data for NTLA-2001, demonstrating the ability to precisely edit target cells within the body to treat genetic disease with a single intravenous infusion of CRISPR. Landmark data published in the New England Journal of Medicine in August 2021.

November 2022

Interim Results From Landmark Clinical Trial of NTLA-2001

Updated interim data from the cardiomyopathy arm of ongoing Phase 1 study of NTLA-2001, an investigational CRISPR therapy for the treatment of transthyretin (ATTR) amyloidosis.

November 2022

Positive Interim Data from Second Investigational In Vivo Genome Editing Candidate

Intellia announces positive interim results from first-in-human study of NTLA-2002 for the treatment of hereditary angioedema (HAE).

March 2023

FDA clearance of IND application for NTLA-2002

The U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).

Illustration of how NTLA-2002 works
October 2023

FDA clearance of IND application for NTLA-2001

Intellia announces FDA clearance of Investigational New Drug (IND) application to initiate a pivotal Phase 3 trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

January 2024

NTLA-2002 clinical data published in the New England Journal of Medicine

Intellia announces that interim results from the Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of Medicine (NEJM).

NEJM NTLA-2002 publication